1. Plasma miRNA profile at COVID-19 onset predicts severity status and mortality
- Author
-
Asier Fernández-Pato, Ana Virseda-Berdices, Salvador Resino, Pablo Ryan, Oscar Martínez-González, Felipe Peréz-García, María Martin-Vicente, Daniel Valle-Millares, Oscar Brochado-Kith, Rafael Blancas, Amalia Martínez, Francisco C. Ceballos, Sofía Bartolome-Sánchez, Erick Joan Vidal-Alcántara, David Alonso, Natalia Blanca-López, Ignacio Ramirez Martinez-Acitores, Laura Martin-Pedraza, María Ángeles Jiménez-Sousa, and Amanda Fernández-Rodríguez
- Subjects
sars-cov2 ,covid-19 ,mirnas ,severity ,mortality ,Infectious and parasitic diseases ,RC109-216 ,Microbiology ,QR1-502 - Abstract
Background MicroRNAs (miRNAs) have a crucial role in regulating immune response against infectious diseases, showing changes early in disease onset and before the detection of the pathogen. Thus, we aimed to analyze the plasma miRNA profile at COVID-19 onset to identify miRNAs as early prognostic biomarkers of severity and survival. Methods and results Plasma miRNome of 96 COVID-19 patients that developed asymptomatic/mild, moderate and severe disease was sequenced together with a group of healthy controls. Plasma immune-related biomarkers were also assessed. COVID-19 patients showed 200 significant differentially expressed (SDE) miRNAs concerning healthy controls, with upregulated putative targets of SARS-CoV-2, and inflammatory miRNAs. Among COVID-19 patients, 75 SDE miRNAs were observed in asymptomatic/mild compared to symptomatic patients, which were involved in platelet aggregation and cytokine pathways, among others. Moreover, 137 SDE miRNAs were identified between severe and moderate patients, where miRNAs targeting the SARS CoV-2 genome were the most strongly disrupted. Finally, we constructed a mortality predictive risk score (miRNA-MRS) with ten miRNAs. Patients with higher values had a higher risk of 90-days mortality (hazard ratio=4.60; p-value
- Published
- 2022
- Full Text
- View/download PDF